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Abstract
Background: Interrogate the impact of IKZF1 deletion on therapy-outcomes of adults with common B-cell acute
lymphoblastic leukemia.
Methods: One hundred sixty-five consecutive adults with common B-cell ALL were tested for IKZF1 deletion and
for BCR/ABL. Deletions in IKZF1 were detected using multiplex RQ-PCR, multiplex fluorescent PCR, sequence analysis
and multiplex ligation-dependent probe amplification (MLPA). BCR/ABL was detected using RQ-PCR. All subjects
received chemotherapy and some also received an allotransplant and tyrosine kinase-inhibitors. Multivariate analyses
were done to identify associations between IKZF1 deletion and other variables on non-relapse mortality (NRM),
cumulative incidence of relapse (CIR), leukemia-free survival (LFS) and survival.
Results: Amongst subjects achieving complete remission those with IKZF1 deletion had similar 5-year non-relapse
mortality (NRM) (11 % [2–20 %] vs. 16 % [4–28 %]; P = 0.736), a higher 5-year cumulative incidence of relapse (CIR)
(55 % [35–76 %] vs. 25 % [12–38 %]; P = 0.004), and worse 5-year leukemia-free survival (LFS) (33 % [16–52 %] vs.
59 % [42–73 %]; P = 0.012) and survival (48 % [33–62 %] vs. 75 % [57–86 %]; P = 0.002). In multivariate analyses
IKZF1 deletion was associated with an increased relapse (relative risk [RR] =2.7, [1.4–5.2]; P = 0.002), a higher risk of
treatment-failure (inverse of LFS; RR = 2.1, [1.2–3.6]; P = 0.007) and a higher risk of death (RR = 2.8, [1.5–5.5]; P = 0.002).
The adverse impact of IKZF1 deletion on outcomes was stronger in subjects without vs. with BCR-ABL1 and in subjects
receiving chemotherapy-only vs. an allotransplant.
Conclusions: IKZF1 deletion was independently-associated with a higher relapse risk and worse LFS and survival in
adults with common B-cell ALL after adjusting for other prognostic variables and differences in therapies. These data
suggest IKZF1 deletion may be a useful prognostic variable in adults with common B-cell ALL, especially in persons
without BCR-ABL1 and those receiving chemotherapy-only. Transplants appear to overcome the adverse impact of
IKZF1 deletion on therapy-outcomes but confirmation in a randomized study is needed. The trial was registered
in 2007 with the Beijing Municipal Government (Beijing Municipal Health Bureau Registration N: 2007–1007).
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Background
About 85 % of cases of adult acute lymphoblastic leukemia
(ALL) develop from B-cells. Identification of biological de-
terminants of treatment-outcomes is incomplete. Consen-
sus prognostic variables include age, gender, WBC level at
diagnosis, cytogenetic abnormalities, BCR-ABL1, central
nervous system (CNS) leukemia, time to initial response
and detection of measureable residual disease (MRD) after
induction and consolidation therapies [1–5]. However, ana-
lyses of receiver-operator characteristic (ROC) curves indi-
cate only about one-half of the variability in subject-level
outcomes is explained by known prognostic variables [6].
Genome-wide analyses indicate IKZF1 mutations are
common in ALL and are associated with BCR-ABL1 [7, 8].
IKZF1 encodes the Ikaros transcription factor, a member
of a family of zinc-finger nuclear proteins required for
normal lymphoid development [9]. Intra-genic deletions
in IKZF1 generate aberrant isoforms [8, 10]. The role of
IKZF1 deletions is extensively-evaluated in children with
ALL and is the most common genetic marker associated
with a poor prognosis [11–15]. IKZF1 mutations are also
common in adults with B-cell ALL and are also associated
with poor prognosis in persons with concurrent BCR-
ABL1 [16–18]. Few data are available on the role of IKZF1
deletions in adults with common B-cell ALL. In prelim-
inary analyses we found frequent IKZF1 deletions in
this population. Based on these data we interrogated
associations between IKZF1 deletion and prognosis in a
series of adults with common B-cell ALL.
Methods
Subjects
Between April, 2007 and December, 2012 165 newly-
diagnosed subjects ≥14 years old with common B-cell
ALL were seen at Peking University People’s Hospital,
Peking University Institute of Hematology (Beijing, China).
3 subjects with severe co-morbidities were ineligible for
induction chemotherapy (2 had an IKZK1 deletion) and
excluded from further analyses. The 162 eligible subjects
received remission-induction chemotherapy. Those achiev-
ing complete remission received 2 cycles of consolidation
chemotherapy after which they could continue receiving
chemotherapy or receive an allotransplant based on donor
availability, finances and physician and subject choice.
Physicians and subjects were blinded to results of IKZF1-
testing. Subjects were followed until death, loss to
follow-up or December, 2014. Written informed consent
was obtained from adult subjects and from parents of
minors in accordance with the Declaration of Helsinki.
The study was approved by the Ethics Committee of
Peking University People’s Hospital. Subjects receiving
post-remission chemotherapy were included in a Chinese
Clinical Trial registered in 2007 with the Beijing Municipal
Government (Beijing Municipal Health Bureau Registration
N: 2007–1007).
Diagnosis and response criteria
Diagnosis of ALL was based on ≥20 % bone marrow
lymphoblasts. Common-B-cell type was defined as cases
with CD10, CD19, CD22 and CD79a expression and no
surface immunoglobulin by flow cytometry [19]. Complete
remission was defined bone marrow lymphoblasts < 5 %,
neutrophils >1.0 × 10E + 9/L, platelets >100 × 10E + 9/L,
no extra-medullary disease and no loss of these features
for >4 weeks. Relapse was defined as leukemia recurrence
at any site in persons in complete remission.
Cytogenetic and molecular analyses
Cytogenetic analyses were performed by using standard
G-banding [20]. BCR-ABL1 transcripts, MLL rearrange-
ment and E2A/PBX1 transcripts were detected with
quantitative real-time polymerase chain reaction (RQ-
PCR) [21, 22]. IKZF1 deletions were detected using
multiplex RQ-PCR, multiplex fluorescent PCR, sequence
analysis [23] and multiplex ligation-dependent probe ampli-
fication (MLPA) (MRC-Holland, Amsterdam, Netherlands)
performed using SALSA MLPA kit P202-B1 IKZF1. Focal
IKZF1 gene deletions (deletions of exons 4–7, 4–8, 2–7, 2–
8 and other focal deletions identified by MLPA analysis)
were defined as IKZF1 deletion in the present study.
Chemotherapy
One hundred six subjects without BCR/ABL received
induction chemotherapy with 1–2 cycles of CODPL
(cyclophosphamide, vincristine, daunorubicin, prednis-
one and L-asparaginase). 56 subjects with BCR-ABL1 re-
ceived induction chemotherapy with the same regimen
without L-asparaginase and 48 also received imatinib,
400 mg/d, beginning at diagnosis. 5 were later switched
to dasatinib, 1 to nilotinib and 1 to ponatinib because of
resistant mutations. Data regarding IKZF1 deletion were
not used to determine induction chemotherapy. Subjects
achieving complete remission (CR) received 2 cycles
consolidation chemotherapy with hyper-CVAD (cyclo-
phosphamide, vincristine, doxorubincin, dexamethasone,
cytarabine and methotrexate). All subjects received CNS
prophylaxis with intrathecal methotrexate, cytarabine
and dexamethasone for ≥8 doses during induction and
consolidation therapy. Details of these regimens are re-
ported [24]. Subjects remaining in CR continued receiving
chemotherapy until the completed 6 more cycles, received
an allotransplant or relapsed. Post-consolidation therapy
was with 6-mercaptopurine, 50 mg/mE2/d PO and metho-
trexate, 20 mg/mE2/d PO, each once weekly. 28 subjects
with BCR-ABL1 receiving an allotransplant also received
posttransplant tyrosine kinase-inhibitor (TKI) therapy. 17
subjects with BCR-ABL1 receiving post-consolidation
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chemotherapy but no allotransplant also received post-
consolidation TKI therapy. Decisions to give or not to give
TKI therapy post-consolidation or posttransplant were
based on finances and subject and/or physician preference
and without knowing results of IKZF1 deletion-testing.
Allotransplants
Ninety-two subjects (64 %) received an allotransplant, 24
(26 %) from an HLA-identical sibling and 68 (74 %)
from a HLA-haplotype-mismatched related donor (1
HLA-antigen mismatch [N = 4], 2 HLA-antigen mis-
matches [N = 20] and 3 HLA-antigen mismatches [N =
44]). Conditioning was with busulfan and cyclophospha-
mide. Anti-thymocyte globulin was given pretransplant
when the donor was a HLA-haplotype-mismatched rela-
tive. Donors received recombinant human G-CSF after
which bone marrow and blood cells were collected and
infused into the recipient. Graft-vs.-host disease prophy-
laxis was with cyclosporine, mycophenolatemofetil and
short-term methotrexate. Haematological relapses were
treated with donor mononuclear cells infusions. Some
subjects received a 2nd transplant from the same or a dif-
ferent donor. Details are reported [25, 26].
Endpoints and statistical analyses
Haematologic response was analyzed weekly for the first
3 months and monthly thereafter. Cytogenetic and mo-
lecular responses were analyzed every 3 months for the
first 6 months and every 6–12 months thereafter.
Leukemia-free survival (LFS) was calculated from the
date of 1st complete remission to the date of first relapse
or death in complete remission. Survival was calculated
from 1st complete remission to the date of death from
any cause. Observations were censored at the date of last
contact or December, 2014 when no events were ob-
served. In survival analyses subjects receiving an allo-
transplant who relapsed were censored at the time they
received a donor blood cell infusion or a second allo-
transplant. Last follow-up was December, 2014. Relapse
was defined as 1st hematologic relapse regardless of site.
Independence of categorized parameters was calculated
using Chi-square test (or Fisher Exact test). Distribution
of continuous variables was calculated using Wilcoxon
two sample tests. Survival functions were estimated by
the Kaplan-Meier method and compared by the log-rank
test. Cumulative incidences were estimated for NRM
and relapse to accommodate competing risks. NRM was
a competing risk for relapse and death from any cause was
a competing risk for relapse. A Cox proportional hazard
regression model was used to determine associations
between IKZF1 deletion and other variables with relapse,
NRM, treatment-failure and death. The variables to be
considered in the multivariate models were: IKZF1 dele-
tion (Y/N), BCR-ABL1 (Y/N), gender, age (≥ vs. < 35 years),
WBC (≥ vs. < 30 × 10E + 9/L), hypo-diploid karyotype
(Y/N), complex karyotype and treatment (chemother-
apy vs. allotransplant). CNS, MLL rearrangement or
E2A-PBX1 transcripts and TKI were not considered in
the multivariate analysis because of either too few sub-
jects in a category or missing data. Assumption of pro-
portional hazards for each factor in the Cox model was
tested using time-dependent covariates. A stepwise
model selection approach was used to identify all sig-
nificant risk factors. Each step of model building con-
tained the main effect for IKZF1 deletion. Factors
which are significant at a P = 0.05 level were kept in
the final model. Potential interactions between main
effect and all significant risk factors were tested. Ana-
lyses were performed by SPSS software version 19.0
(Chicago, IL, USA), Graphpad Prism 5.01 (San Diego,
California, USA) and R version 3.1.2. Difference with
P < 0.05 was considered significant.
Results
Subjects
Sixty-eight IKZF1 local deletions were detected of sub-
jects achieving complete remission including 32 (47 %)
subjects with type Δ4–7, 17 (25 %) with type Δ2–7, 3
with type Δ4–8, 10 (15 %) with type Δ2-8 and 6 with
other deletions. 6 other deletions identified by MLPA
analysis were undetectable by multiplex PCR. Propor-
tions of dominant negative isoforms (Δ4–7 deletion) and
haplotype-insufficiency (other local deletion types) were
comparable. The proportion of Δ4–7 deletion in subjects
with BCR-ABL1 was higher than in subjects without
BCR-ABL1 (20/31 vs. 12/37; P = 0.008). Baseline subject-
and disease-related variables of subjects achieving CR
are shown in Table 1. Subjects with IKZF1 deletion
were older (34 years [15–70] vs. 22 [14–59]; P = 0.045),
had a significantly higher WBC (14 [2–435] vs. 9 [0.5–168];
P = 0.008) and were more likely to have BCR-ABL1 (75 %
vs. 25 %; P < 0.01) and t (9; 22) (72 % vs. 28 %; P < 0.05)
than subjects without IKZF1 deletion.
Outcomes and IKZF1 deletion
Median follow-up was 22 months (range, 2–91 months).
146 (90 %) subjects achieved complete remission. 2 sub-
jects in the IKZF1 cohort relapsing during consolidation
chemotherapy and before they could be assigned to
further chemotherapy-only or an allotransplant were
excluded from further analyses. 5-year NRM in the
144 subjects was 14 % (95 % confidence interval [CI],
6–22 %), 5-year CIR was 38 % (27–49 %), 5-year LFS,
48 % (36–59 %) and 5-year survival, 63 % (51–72 %).
In subjects with IKZF1 deletion 5-year NRM was 11 %
(2–20 %) vs. 16 % (4–28 %; P = 0.736, Fig. 1a) for subjects
without IKZF1 deletion. In subjects with IKZF1 deletion
5-year CIR was 55 % (35–76 %) vs. 25 % (12–38 %;
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P = 0.004; Fig. 1b) for subjects without IKZF1 dele-
tion. In subjects with IKZF1 deletion 5-year LFS was
33 % (16–52 %) vs. 59 % (42–73 %; P = 0.012; Fig. 1c)
in subjects without IKZF1 deletion. In subjects with
IKZF1 deletion 5-year survival was 48 % (33–62 %)
vs. 75 % (57–86 %; P = 0.002; Fig. 1d) in subjects
without IKZF1 deletion. There were 26 deaths in
IKZF1 deletion cohort, 20 from leukemia and 6 from
other causes. There were 15 deaths in the no IKZF1 dele-
tion cohort, 5 from leukemia and 10 from other causes.
Prognoses were similar in subjects with a dominant nega-
tive IKZF1 isoform compared to haplotype-insufficient
subjects: 4-year NRM 14 % (1–27 %) vs. 8 % (0–19 %;
P = 0.32); 4-year CIR 50 % (29–70 %) vs. 44 % (23–64 %;
P = 0.54); 4-year LFS 36 % (18–55 %) vs. 49 % (28–67 %;
P = 0.20) and 4-year survival 45 % (23–65 %) vs. 51 %
(30–69 %; P = 0.53).
Because IKZF1 deletion and BCR-ABL1 were con-
founded (r = 0.407; P < 0.001), we analyzed the impact of
IKZF1 deletion in subjects with and without BCR-ABL1.
Amongst the 94 subjects without BCR-ABL1 the 65
subjects with IKZF1 deletion had a significantly higher
4-year CIR than the 29 subjects without IKZF1 deletion
(51 % [30–72 %] vs. 17 % [7–28 %]; P = 0.002). These
subjects also had worse LFS (33 % [15–52 %] vs. 72 %
[58–82 %]; P = 0.001) and worse survival (46 % [24–
66 %] vs.84 % [71–91 %]; P = 0.000). There was no sig-
nificant difference in their NRM (17 % [1–32 %] vs.
11 % [2–19 %]; P = 0.525). In contrast, there were no sig-
nificant differences in NRM, CIR, LFS or survival in sub-
jects with BCR-ABL1 with and without IKZF1 deletion.
Interaction between IKZF1 deletion and post-remission
therapy
Fifty-two subjects achieving remission received
chemotherapy-only. 3-year NRM was 15 % (3–26 %),
3-year CIR, 53 % (36–70 %), 3-year LFS, 32 % (17–49 %)
and 3-year survival, 44 % (23–64 %). Subjects with IKZF1
deletion (N = 28) had similar 3-year NRM (14 % [0–29 %]
vs. 15 % [0–33 %]; P = 0.958), 3-year CIR (73 % [41–
100 %] vs. 39 % [16–61 %]; P = 0.099), worse 3-year
LFS (14 % [1–41 %] vs. 46 % [23–66 %]; P = 0.084) and
Table 1 Subject- and disease-related variables
Variable All subjects IKZF1-deleted IKZF1 wild type P-value
N 146 68 (47 %) 78 (53 %)
Age, y
Median (range) 27 (14–70) 34 (15–70) 22 (14–59) 0.045
Gender
Male 72 33 (46 %) 39 (54 %) 0.859
WBC (×10E + 9/L)
Median (range) 10 (0.5-435) 14 (2–435) 9 (0.5-168) 0.008
Hemoglobin (g/L)
Median (range) 90 (23–157) 92 (35–148) 89 (23–157) 0.300
Platelets (×10E + 9/L)
Median (range) 57 (0.2–313) 58 (0.2–311) 52 (2–313) 0.600
Bone marrow blasts, %
Median (range) 87 (28–99) 86 (28–98) 88 (28–99) 0.300
BCR-ABL1 52 39 (75 %)a 13 (25 %)b 0.000
Cytogenetics
Normal 47 19 (40 %) 28 (60 %) 0.305
Abnormal 81 38 (47 %) 43 (53 %)
t(9;22) 43 31 (72 %) 12 (28 %) 0.000
t(X;2)(p22;p21) 1 1 0
del(9)(p13) 1 1 0
inv(9) 2 1 1
47,+X 1 1 0
Complex 33 3 30
Unknown 18 11 (61 %) 7 (39 %)
a8 subjects with BCR-ABL1 had no t(9;22) including 5 with insufficient metaphases, 2 with an abnormal karyotype but not t(9;22) and 1 with a normal karyotype
b1 subject with BCR-ABL1 had a normal karyotype
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worse 3-year survival (15 % [1–44 %] vs.78 % [48–92 %];
P = 0.001; Fig. 2a-d) compared with subjects without
IKZF1 deletion.
Ninety-two (64 %) subjects achieving remission received
an allotransplant. 5-year NRM was 14 % (4–24 %), 5-year
CIR, 31 % (17–45 %), 5-year LFS, 56 % (40–70 %) and
5-year survival, 71 % (56–81 %). Subjects with IKZF1 dele-
tion (N = 38) had a significantly higher 5 year CIR (47 %
[21–73 %] vs. 20 % [3–36 %]; P = 0.024) but similar 5 years
NRM (9 % [0–19 %] vs. 17 % [1–33 %]; P = 0.567), 5-year
LFS (44 % [21–66 %] vs. 64 % [40–80 %]; P = 0.119) and
5-year survival (64 % [44–79 %] vs.75 % [53–88 %]; P =
0.332; Fig. 2e-h).
Multivariate analyses
IKZF1 deletion was independently associated with an in-
creased relapse risk (RR = 2.7 [1.4–5.2]; P = 0.002), a
greater risk of treatment-failure (RR = 2.1 [1.2–3.6]; P =
0.007) and a greater risk of death (RR = 2.8 [1.5–5.5];
P = 0.002). An adverse impact of IKZF1 on survival was
observed in subjects receiving chemotherapy-only (RR =
6.5 [2.1–19.7]; P = 0.001) but not those receiving an al-
lotransplant (RR = 1.5 [0.7–3.6]; P = 0.336). Other vari-
ables associated with relapse were chemotherapy-only
(RR = 6.0 [3.1–11.6]; P < 0.0001) and male gender (RR =
2.0 [1.1–3.9]; P = 0.030). Chemotherapy-only was also
associated with greater risk of treatment-failure (RR = 4.4
[2.6–7.6]; P < 0.0001) and death (RR = 4.1 [2.1–7.8]; P <
0.0001). Age ≥35 years was the only variable associated
with NRM (RR = 3.0 [1.1–8.7]; P = 0.039). Results of multi-
variate analyses are shown in Table 2.
Discussion
IKZF1 deletion was independently-associated with
higher risks of relapse, treatment-failure and death in
adults with common B-cell ALL compared with similar
subjects without IKZF1 deletion. Although IKZF1 deletion
was confounded with BCR-ABL1, the adverse impact per-
sisted after adjusting for BCR-ABL1 and parallels similar
findings in children with B-cell ALL [12, 15]. The adverse
impact of IKZF1 deletion operated mainly in subjects
without BCR-ABL1. In subjects receiving an allotransplant
the adverse impact of IKZF1 deletion was less than in
those receiving chemotherapy-only suggesting a benefit
for using transplants in subjects with IKZF1 deletion.
Our analysis was complex because of confounding be-
tween IKZF1 deletion, BCR-ABL1 and post-remission
therapy (chemotherapy-only vs. an allotransplant). We
used multivariate analyses to resolve this confounding.
We found IKZF1deletion, chemotherapy-only, gender and
age were significantly associated with outcomes whereas
other variables including WBC, cytogenetics and BCR-ABL1
Fig. 1 a Cumulative incidence of non-relapse mortality (NRM); b cumulative incidence of relapse (CIR); c leukemia-free survival (LFS); and d survival of
subjects with and without IKZF1 deletion since first complete remission
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were not. This is surprising, especially the lack of a
significant association between BCR-ABL1 with outcomes.
There are several possible explanations. One is insuffi-
cient statistical power; there were relatively few subjects
with adverse cytogenetics, hypo-diploidly or a complex
karyotype. However, low power cannot explain the lack
of a significant association between BCR-ABL1 and
outcomes. As indicated, IKZF1 deletion and BCR-ABL1
were confounded. Subjects with BCR-ABL1 received
different initial therapy than subjects without BCR-
ABL1 including TKIs in 90 % and an allotransplant in
58 %. If these interventions were highly-effective they
could mitigate the adverse impact of BCR-ABL1. This
notion is supported by the observation the adverse
Fig. 2 NRM, CIR, LFS and survival of subjects with and without IKZF1 deletion receiving chemotherapy-only (a-d) or an allotransplant (e-h) since 1st
complete remission. Abbreviations: NRM, non-relapse mortality; CIR, cumulative incidence of relapse; LFS, leukemia-free survival; CR1, 1st complete remission
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predictive impact of IKZF1 deletion was detected in
subjects without but not in those with BCR-ABL1 and
in subjects receiving chemotherapy-only but not in
those receiving an allotransplant.
Our conclusions contrast with data from a study of 83
subjects with BCR-ABL1 which reported IKZF1 deletions
were associated with more relapses and worse LFS [16].
However, there are several important differences in sub-
jects (we studied only subjects with common B-cell ALL)
and post-remission therapy (few of their subjects received
an allotransplant). Our conclusion is similar to reports in
children with BCR-ABL1 in whom IKZF1 deletion is asso-
ciated with worse outcomes and with results of a recent
meta-analysis indicating IKZF1 deletion is independently-
associated with worse outcomes in children and adults
with ALL [27, 28].
There are several limitations to our study. One, as
discussed, is confounding between IKZF1 deletion, BCR-
ABL1 and post-remission therapy. Confounding is diffi-
cult to satisfactorily sort out in multivariate analyses but
our data suggest that IKZF1 deletion was independently-
associated with higher risks of relapse, treatment-failure
and death in subjects without BCR-ABL1. Second, subjects
with BCR-ABL1 received different induction, consolida-
tion and post-remission therapies than those without
BCR-ABL1. However, therapy-assignment was made with-
out knowing IKZF1 deletion data and we tried to account
for this complexity in multivariate analyses. Another limi-
tation is we did not include several potentially important
variables (CNS leukemia, MLL rearrangement, E2A-PBX1
transcripts and TKI therapy) in the multivariate analyses
because of too few subjects or missing data. The sum of
these potential limitations means our conclusions require
confirmation in prospective, randomized studies.
Conclusion
In adults with common B-cell ALL achieving complete
remission IKZF1 mutation was independently-associated
with a higher CIR and worse survival than subjects with-
out IKZF1 mutation. These differences were greater in
subjects receiving post-remission chemotherapy than in
subjects receiving an allotransplant. We suggest a ran-
domized trial to confirm our observation.
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